X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA LUPIN LTD ALEMBIC PHARMA/
LUPIN LTD
 
P/E (TTM) x 27.3 28.3 96.7% View Chart
P/BV x 5.5 3.0 186.4% View Chart
Dividend Yield % 0.6 0.6 109.7%  

Financials

 ALEMBIC PHARMA   LUPIN LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
LUPIN LTD
Mar-18
ALEMBIC PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs6451,465 44.0%   
Low Rs470727 64.6%   
Sales per share (Unadj.) Rs166.1349.6 47.5%  
Earnings per share (Unadj.) Rs21.95.6 394.0%  
Cash flow per share (Unadj.) Rs27.529.6 92.9%  
Dividends per share (Unadj.) Rs4.005.00 80.0%  
Dividend yield (eoy) %0.70.5 157.3%  
Book value per share (Unadj.) Rs117.8300.3 39.2%  
Shares outstanding (eoy) m188.52452.08 41.7%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x3.43.1 107.1%   
Avg P/E ratio x25.5197.2 12.9%  
P/CF ratio (eoy) x20.337.1 54.7%  
Price / Book Value ratio x4.73.6 129.7%  
Dividend payout %18.390.0 20.3%   
Avg Mkt Cap Rs m105,090495,502 21.2%   
No. of employees `000NA17.0 0.0%   
Total wages/salary Rs m6,22828,647 21.7%   
Avg. sales/employee Rs ThNM9,273.6-  
Avg. wages/employee Rs ThNM1,681.0-  
Avg. net profit/employee Rs ThNM147.4-  
INCOME DATA
Net Sales Rs m31,308158,042 19.8%  
Other income Rs m701,504 4.7%   
Total revenues Rs m31,378159,545 19.7%   
Gross profit Rs m6,43131,475 20.4%  
Depreciation Rs m1,05510,859 9.7%   
Interest Rs m342,044 1.7%   
Profit before tax Rs m5,41320,076 27.0%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m-8135 -229.8%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m1,2042,885 41.7%   
Profit after tax Rs m4,1282,513 164.3%  
Gross profit margin %20.519.9 103.1%  
Effective tax rate %22.214.4 154.8%   
Net profit margin %13.21.6 829.4%  
BALANCE SHEET DATA
Current assets Rs m18,247122,095 14.9%   
Current liabilities Rs m11,23550,956 22.0%   
Net working cap to sales %22.445.0 49.8%  
Current ratio x1.62.4 67.8%  
Inventory Days Days8685 101.2%  
Debtors Days Days61120 51.2%  
Net fixed assets Rs m20,035129,876 15.4%   
Share capital Rs m377904 41.7%   
"Free" reserves Rs m21,824134,866 16.2%   
Net worth Rs m22,201135,771 16.4%   
Long term debt Rs m5,00064,245 7.8%   
Total assets Rs m39,411263,054 15.0%  
Interest coverage x160.210.8 1,479.9%   
Debt to equity ratio x0.20.5 47.6%  
Sales to assets ratio x0.80.6 132.2%   
Return on assets %10.61.7 609.8%  
Return on equity %18.61.9 1,004.8%  
Return on capital %19.73.7 530.3%  
Exports to sales %46.40-   
Imports to sales %10.50-   
Exports (fob) Rs m14,535NA-   
Imports (cif) Rs m3,288NA-   
Fx inflow Rs m14,72253,141 27.7%   
Fx outflow Rs m7,02619,335 36.3%   
Net fx Rs m7,69633,807 22.8%   
CASH FLOW
From Operations Rs m3,12417,512 17.8%  
From Investments Rs m-8,844-14,073 62.8%  
From Financial Activity Rs m5,026-14,921 -33.7%  
Net Cashflow Rs m-693-11,482 6.0%  

Share Holding

Indian Promoters % 74.1 46.6 159.0%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 2.9 11.3 25.7%  
FIIs % 9.1 31.9 28.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.1 137.6%  
Shareholders   49,328 98,259 50.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS